Summary
Ade Ojewole is a senior technology and drug-discovery leader with 11+ years of experience at the intersection of AI, structural biology, and software engineering, currently leading Global AI and Accelerated Computing at Eli Lilly. He combines a PhD in structural bioinformatics and postdoctoral work in computational drug discovery with hands-on systems experience from roles at NVIDIA and Genentech to translate ML and accelerated computing into preclinical and commercial workflows. Ade has driven GenAI strategy across clinical, regulatory, manufacturing, and commercial domains, bridging scientific rigor with business strategy to advance therapeutic development. He is comfortable moving between deep technical domains (computational protein design, statistical mechanics, algorithms) and executive-facing commercialization and partnerships. Based in San Diego, he mixes academic depth with enterprise-scale product delivery and a track record of shaping industry partnerships and platform strategy. An often-overlooked strength is his ability to operationalize cutting-edge research on accelerated hardware into reproducible pipelines that de-risk translation to the clinic.
11 years of coding experience
15 years of employment as a software developer
Doctor of Philosophy (Ph.D.), Doctor of Philosophy (Ph.D.) at Duke University
Master of Science (M.Sc.), Master of Science (M.Sc.) at University of Michigan
Stanford University